Brain Implant Detects Cancer: First Human Trials

What happened?

On December 5, 2024, Coherence Neuro announced that three patients have received brain implants designed to detect the presence of cancer cells. The device, a brain-computer interface (BCI), not only monitors brain activity for tumor signals but could in the future apply electrical stimulation to inhibit cancer growth. The tests are being conducted as part of an initial human clinical trial, according to Wired. This milestone marks the first time a BCI has been implanted for an oncological purpose in humans, differentiating it from previous projects focused on motor restoration or communication.

Why is it important?

This advance represents a paradigm shift in neurological oncology. Until now, detecting tumor recurrences required MRI scans or invasive biopsies, methods that do not offer continuous monitoring. An implant that constantly monitors the brain could detect changes much earlier, enabling early interventions. Additionally, the ability to apply localized electrical stimulation could slow or stop tumor growth without the side effects of chemotherapy or radiotherapy. Although the study is in an early phase, it lays the groundwork for personalized, real-time medicine for brain cancer. According to the American Cancer Society, gliomas account for approximately 30% of primary brain tumors, and their five-year survival rate is less than 10% in aggressive cases like glioblastoma. This approach could improve those numbers if its efficacy is confirmed.

Consequences and context

If results are positive, this approach could reduce mortality from gliomas, one of the most aggressive cancers. It also opens the door to similar implants for other solid tumors, such as lung or breast cancers with brain metastases. However, challenges remain: device durability, the body's immune response, and the real effectiveness of electrical stimulation in stopping cancer. In the past, other BCIs like Neuralink have focused on restoring motor or communication functions, but Coherence Neuro targets oncology, a niche with enormous potential impact. It is worth noting that electrical stimulation as an anticancer therapy has been explored in other contexts: for example, Tumor Treating Fields (TTFields) approved by the FDA for glioblastoma, which use alternating electric fields applied externally. However, TTFields require the patient to wear an external device and do not offer continuous monitoring. Coherence Neuro's implant, in contrast, is completely internal and could operate autonomously. Moreover, the current trial is conducted under strict safety protocols, and the company plans to expand it to more hospital centers in 2025, according to statements to Wired.

What readers should know

• The trial includes only three patients, so results are preliminary and do not allow generalizable conclusions.
• The device is not yet approved by regulatory agencies like the FDA; it is an experimental feasibility and safety study.
• Electrical stimulation as an anticancer therapy has been explored in other contexts (e.g., Tumor Treating Fields), but not in chronic brain implants. The key difference is the integration of detection and treatment in a single device.
• Coherence Neuro plans to expand the trial to more hospital centers in 2025, which will allow data collection from a larger sample.
• The durability of the implant is unknown; electronic devices in the brain can degrade over time or generate glial scars that affect their function.
• The potential cost of treatment has not yet been discussed, but it could be high, raising questions about equitable access.

“This is the first step toward a closed-loop system where the implant detects and treats cancer in real time, without external intervention,” a Coherence Neuro spokesperson told Wired. “Our goal is to transform brain cancer management, moving from a reactive approach to a proactive and continuous one.”

In summary, the news is promising but should be taken with caution. The scientific community awaits more robust data on safety and efficacy before considering this approach as a viable clinical option. While the concept is innovative, the history of neurotechnology is full of early promises that do not always materialize. For example, early BCI trials for paralysis showed encouraging results, but their clinical adoption has been slow due to technical and regulatory challenges. Coherence Neuro faces a similar path, but its focus on oncology could accelerate interest and investment, given the devastating impact of brain cancer.